Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

This trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC). Its primary objective is to evaluate the safety, tolerability, pharmacokinetic profiles, and efficacy of transcatheter arterial infusion of HA131 combined with systemic therapy in the second-line treatment of participants with advanced HCC.

NCT Number	NCT07282509
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	Advanced Hepatocellular Carcinoma (HCC)
Enrollment	116 participants
Start Date	2025-12-23
Primary Completion	2028-06-26 (estimated)
Study Completion	2029-02-03 (estimated)
Updated on ClinicalTrials.gov	2025-12-15